Business Wire

TX-TQ-DELTA

30.5.2019 00:13:05 CEST | Business Wire | Press release

Share
Significant Patent Win for TQ Delta

TQ Delta LLC, a technology development and licensing firm, secured another favorable judgment last week when a Delaware federal jury found that 2Wire Inc. infringed three of TQ Delta’s patents related to Digital Subscriber Line (“DSL”) technology. 2Wire is a subsidiary of ARRIS Solutions, which was recently acquired by CommScope Inc.

TQ Delta’s patents cover important memory sharing capabilities for DSL modems and central office equipment, among other inventions. TQ Delta notes that these inventions are widely employed not just in the United States, but around the world.

This ruling represents another victory for TQ Delta’s ongoing licensing business. Earlier this year, the High Court of Justice of England and Wales also found in favor of TQ Delta on another patent from its deep portfolio of DSL inventions. The UK Proceeding against ZyXEL Communications UK Ltd and its Danish parent company, ZyXEL Communications A/S (both subsidiaries of Unizyx Holding Corporation) found TQ Delta’s European Patent (UK) 1 453 268 valid and infringed, as well as essential to the standards for ADSL2 and VDSL2. The Court granted an immediate injunction and award of costs against the ZyXEL defendants. ZyXEL defendants have appealed some elements of the judgment and that appeal is pending. TQ Delta’s worldwide portfolio spans a broad range of standard essential patents (“SEPs”) and non-SEPs that are central to key broadband network technologies. In addition to validation by courts in the US and UK, TQ Delta has successfully licensed its technology to key market participants.

The most recent verdict was announced on May 23 following a nearly four-day trial in the United States District Court for the District of Delaware. After deliberation, the eight-member jury returned a favorable verdict on all eleven counts, finding that 2Wire infringed U.S. Patent nos. 7,836,381, 7,844,882 and 8,276,048, that those patents were not obvious over prior art, and that two certificates of correction were not invalid.

“We are pleased with the jury’s decision affirming the strength and importance of our portfolio of inventions, which are the culmination of years of investment in standards development and communications technologies,” said Abha Divine, Managing Director of TQ Delta.

TQ Delta has supported continued development of DSL markets by maintaining a longstanding business strategy designed to ensure advancements in the technology. “The TQ Delta portfolio and continued investment in the field contributes to the past, present, and future of high-speed DSL connections around the world. We have already licensed several companies to practice the important inventions under our DSL portfolio and will continue to seek to license others through business negotiations,” said Divine.

TQ Delta was represented by McAndrews, Held, and Malloy, Ltd., a firm specializing in intellectual property prosecution, counselling, and dispute resolution.

Lead trial attorney, Peter McAndrews, explained that “The Defendant’s strategy was to trivialize the important inventions at issue. We are pleased that the jury vindicated the inventors’ hard work and our client’s commitment to innovation.”

TQ Delta maintains a sizable patent portfolio for digital communication technology, including DSL.

About TQ Delta

TQ Delta is a technology development and licensing company aimed at providing needed solutions for the communications industry and beyond. The company’s technical investments span nearly two decades of contributions and innovation in the field of communications. TQ Delta’s technologies are used in leading products and services worldwide spanning broadband communications and media distribution. For more information, visit http://www.tqdelta.com .

Contact:

Scott Krady Magnitude, Inc. scott@magnitudegrowth.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release

Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ

Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release

The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College

Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release

As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi

ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release

Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye